Indivi is a TechBio company developing functional biomarkers as drug development tools for neurological diseases in the form of sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision and voice. Indivi is committed to developing future-proof and transformative digital endpoints as deep phenotyping instruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias. Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in data science, clinical development, signal processing engineering, and advanced analytics including computational intelligence. Through end-to-end joint endeavours with biopharmaceutical companies, Indivi is poised to continue its growth in the nascent digital endpoint industry to improve the probability of technical and regulatory success in neuroscience drug development.
Indivi raised undisclosed on September 30, 2022